Abstract
On a new aminoglycoside antibiotic, netilmicin, antibacterial activity against a variety of Gram-negative clinical isolates was determined, and clinical trial on this drug was performed.
The sensitivities of these strains were good in general, but there found almost complete cross resistance between MICs of netilmicin and dibekacin.
Clinically a total of 4 patients including three of respiratory tract and one of urinary tract infections was treated with netilmicin. There was no response in a case of urinary tract infection. In cases of respiratory tract infections, it was evaluated that one was excellent, one was fair and one was poor.
